CN104861014B - A kind of preparation method of Farmorubine Hydrochloride crystallization - Google Patents
A kind of preparation method of Farmorubine Hydrochloride crystallization Download PDFInfo
- Publication number
- CN104861014B CN104861014B CN201510298163.7A CN201510298163A CN104861014B CN 104861014 B CN104861014 B CN 104861014B CN 201510298163 A CN201510298163 A CN 201510298163A CN 104861014 B CN104861014 B CN 104861014B
- Authority
- CN
- China
- Prior art keywords
- ether
- farmorubine hydrochloride
- preparation
- suspension
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 238000002425 crystallisation Methods 0.000 title claims abstract description 37
- 230000008025 crystallization Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000000725 suspension Substances 0.000 claims abstract description 29
- 150000002148 esters Chemical class 0.000 claims abstract description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000012046 mixed solvent Substances 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 150000002170 ethers Chemical class 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- 238000005360 mashing Methods 0.000 claims description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 5
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- RMOUBSOVHSONPZ-UHFFFAOYSA-N Isopropyl formate Chemical compound CC(C)OC=O RMOUBSOVHSONPZ-UHFFFAOYSA-N 0.000 claims description 3
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940011051 isopropyl acetate Drugs 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- RMGHERXMTMUMMV-UHFFFAOYSA-N 2-methoxypropane Chemical compound COC(C)C RMGHERXMTMUMMV-UHFFFAOYSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims description 2
- VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 claims description 2
- 229940017219 methyl propionate Drugs 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- -1 isopropyl acetoacetic ester Chemical compound 0.000 claims 1
- 239000000539 dimer Substances 0.000 abstract description 11
- 239000012535 impurity Substances 0.000 abstract description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
- 238000001914 filtration Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000002240 furans Chemical class 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- KFNNIILCVOLYIR-UHFFFAOYSA-N Propyl formate Chemical class CCCOC=O KFNNIILCVOLYIR-UHFFFAOYSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to the preparation method of Farmorubine Hydrochloride crystallization, the preparation method comprises the following steps：(a) mixed solvent of ester, ether and water is provided, (b) amorphous substance of Farmorubine Hydrochloride is formed into suspension in the in the mixed solvent of step (a) and be beaten, and (c) collects Farmorubine Hydrochloride crystallization from the suspension.The Farmorubine Hydrochloride crystallization purity obtained by preparation method of the present invention is high, and without the impurity such as dimer and catabolite, storage stability is good.
Description
（One）Technical field
The present invention relates to pharmaceutical chemistry synthesis technical field, and in particular to a kind of preparation side of Farmorubine Hydrochloride crystallization
Method.
（Two）Background technology
Epi-ADM and its acid-addition salts, such as Farmorubine Hydrochloride, belonged to anthracycline compound, from 80 years last century
It has been used as treating the cytostatics of a variety of solid tumor types since generation.
The structural formula of Farmorubine Hydrochloride is as follows：
。
American documentation literature US5,091,373 discloses the purposes that Epi-ADM is used to treat tumour.
The preparation method of Epi-ADM, example are described in american documentation literature US4,112,076 and US5,874,550
Such as, Epi-ADM and its acid-addition salts can chemically be synthesized by daunorubicin starting.European patent document EP1990405A1
Epi-ADM can also be prepared by microbial fermentation processes by disclosing.When preparing Epi-ADM, it will usually produce it is organic and
Inorganic impurity, the 25% of the at most reachable prepared product mixtures weight of their ratio.Therefore, to table Ah mould after preparation
It is necessary that element and its acid-addition salts, which carry out purification,.
The method that american documentation literature US4,861,870 provides purification Farmorubine Hydrochloride.Wherein, by means of acetone
Farmorubine Hydrochloride is precipitated out in the aqueous solution and obtain amorphous substance.It is said that can obtain with the method pure hydrochloric acid table Ah
Mycin amorphous substance.
Describe and penetrated by X- in american documentation literature US 7,485,707 and international patent application WO 2010/039159
The some crystal forms for the Farmorubine Hydrochloride that ray diffraction diagram stave is levied, the Farmorubine Hydrochloride known relative to oneself shows to change
Kind heat endurance.The preparation method of these crystal forms is：Hydrophilic organic solvent is added into Farmorubine Hydrochloride, from molten
Crystallization is separated out in liquid or gel.But, when the present inventor repeats the method for these patent documents description, find what is provided in document
Under the conditions of can not obtain the crystallization Farmorubine Hydrochloride with the X-ray diffracting spectrum.
In addition, from prior art, can be formed when preparing or crystallizing Farmorubine Hydrochloride undesirable dimer or
The impurity such as catabolite, the purity for crystallizing Farmorubine Hydrochloride is low.
Therefore, this area stills need to develop the preparation method of the crystallization Farmorubine Hydrochloride of high-purity.
（Three）The content of the invention
There is provided the preparation method that Farmorubine Hydrochloride is crystallized, the system in order to make up the deficiencies in the prior art by the present invention
Preparation Method process is easy, can operate at room temperature.
The present invention is achieved through the following technical solutions：
The preparation method of the Farmorubine Hydrochloride crystallization of the present invention, comprises the following steps：(a) the mixed of ester, ether and water is provided
Bonding solvent, the in the mixed solvent formation of (b) by Farmorubine Hydrochloride amorphous substance in step (a) and is beaten suspension, and (c) from
Farmorubine Hydrochloride crystallization is collected in the suspension.
Preferably, the ester be selected from C3 ~ C5 esters, C3 ~ C5 esters can be Ethyl formate, methyl acetate, ethyl acetate,
Propyl formate, methyl propionate, isopropyl formate, isopropyl acid methyl esters, propyl acetate, isopropyl acetate, ethyl propionate or isopropyl acid
Ethyl ester；It is highly preferred that C3 ~ C5 esters are selected from ethyl acetate or isopropyl acetate.
Preferably, the ether is selected from C3~C6 ethers, and C3~C6 ethers can be methyl ethyl ether, methyl-propyl ether, first
Base isopropyl ether, ether, methyl tertiary butyl ether(MTBE), tetrahydrofuran, 1,4- dioxane, propyl ether or isopropyl ether；It is highly preferred that described
C3~C6 ethers are selected from methyl tertiary butyl ether(MTBE), tetrahydrofuran or isopropyl ether.
Preferably, the percent by volume of step (a) mixed solvent reclaimed water is 5% ~ 30%；It is highly preferred that step (a) mixing is molten
The percent by volume of agent reclaimed water is 10% ~ 20%.
Preferably, the volume ratio of step (a) in the mixed solvent C3 ~ C5 esters and C3~C6 ethers is 3:1~1:3；It is highly preferred that
The volume ratio of step (a) in the mixed solvent C3 ~ C5 esters and C3~C6 ethers is 1:1~1:2.
Preferably, the mass volume ratio of Farmorubine Hydrochloride amorphous substance and mixed solvent is 1g in step (b):2mL~
1g:15mL；It is highly preferred that the mass volume ratio of Farmorubine Hydrochloride amorphous substance and mixed solvent is 1g in step (b):4mL~
1 g:8mL。
Preferably, the temperature of step (b) mashing is 20 DEG C ~ 40 DEG C, and the time of mashing is 2 ~ 6 hours.
Preferably, after the completion of step (b) mashing, suspension is cooled to 0 DEG C ~ -20 DEG C, and be kept stirring at such a temperature
8 ~ 15 hours；It is highly preferred that the cooldown rate of the suspension is 10 DEG C/h ~ 20 DEG C/h.
In step (c), the crystallization separated out in suspension is separated and dried using the conventional method of this area.It is described
Separation, using the conventional method of this area such as filtering, centrifuge；The concrete operations of filtering are：The sample for being intended to separation is placed in
On filter paper, suction filtration is depressurized；The concrete operations of centrifugation are：Be intended to separation sample be placed in centrifuge tube, afterwards at a high speed rotation until
Solid is all sink to centrifugation bottom of the tube.Selectively, solid is washed with suitable solvent, cleaning solvent such as acetone.It is described dry
It is dry, using this area conventional method such as forced air drying or be dried under reduced pressure；Drying equipment is convection oven or vacuum drying oven；It is dry
Dry to be carried out in the case where depressurizing or not depressurizing, preferably pressure is less than 0.09Mpa；Drying temperature is room temperature（About 10 DEG C ~ 30 DEG C）；
Drying time is 10 ~ 72 hours, preferably 10 ~ 48 hours.
The initiation material Farmorubine Hydrochloride amorphous substance of the present invention, can be according to patent document US4,861,870 disclosures
Method prepare.Through high performance liquid chromatography（HPLC）Detection, its purity is about 90% ~ 93%.
The preparation method process of the present invention is easy, can operate at room temperature.Detect, obtained by preparation method of the present invention through HPLC
The purity for the Farmorubine Hydrochloride crystallization arrived is high, and its purity is free of the impurity such as dimer and catabolite up to more than 99%.
After being preserved 2 months under 40 DEG C, 75% relative humidities, its purity is basically unchanged, and still keeps original crystalline state.
（Four）Embodiment
The present invention is limited with further reference to following examples, and the preparation method of the present invention is described in detail in the embodiment.It is right
It should be apparent to those skilled in the art that many changes for preparation condition can be without departing from the present invention
Implement.
Unless otherwise instructed, various reagents used in embodiment are commercially available.
Unless otherwise instructed, the temperature in embodiment is room temperature.
Embodiment 1
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 20ml ethyl acetate, 30 ml tetrahydrochysene furans
The in the mixed solvent muttered with 10ml water.At 30 DEG C, the suspension is beaten 4 hours.Afterwards, progressively with 10 DEG C/h of speed
The suspension is cooled to -10 DEG C, and is kept for -10 DEG C stir 12 hours.Filtering, crystallization is washed with acetone, then is dried in vacuo 24
Hour, obtain Farmorubine Hydrochloride crystallization.Yield 92%, purity 99.3%, the impurity without dimer or catabolite.
Embodiment 2
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 36ml ethyl acetate, 36ml methyl- terts
The in the mixed solvent of butyl ether and 8ml water.At 40 DEG C, the suspension is beaten 3 hours.Afterwards, progressively with 10 DEG C/h of speed
The suspension is cooled to 0 DEG C by rate, and is kept for 0 DEG C stir 10 hours.Filtering, crystallization washed with acetone, then to be dried in vacuo 36 small
When, obtain Farmorubine Hydrochloride crystallization.Yield 91%, purity 99.0%, the impurity without dimer or catabolite.
Embodiment 3
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 11ml ethyl acetate, 22ml tetrahydrochysene furans
The in the mixed solvent muttered with 7ml water.At 20 DEG C, the suspension is beaten 6 hours.Afterwards, progressively will with 15 DEG C/h of speed
The suspension is cooled to -10 DEG C, and is kept for -10 DEG C stir 15 hours.Filtering, crystallization washed with acetone, then to be dried in vacuo 24 small
When, obtain Farmorubine Hydrochloride crystallization.Yield 92%, purity 99.2%, the impurity without dimer or catabolite.
Embodiment 4
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 60ml isopropyl acetates, 30 ml tetrahydrochysenes
The in the mixed solvent of furans and 10ml water.At 30 DEG C, the suspension is beaten 5 hours.Afterwards, progressively with 20 DEG C/h of speed
The suspension is cooled to -20 DEG C by rate, and is kept for -20 DEG C stir 12 hours.Filtering, crystallization is washed with acetone, then is dried in vacuo
36 hours, obtain Farmorubine Hydrochloride crystallization.Yield 90%, purity 99.1%, the impurity without dimer or catabolite.
Embodiment 5
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 12ml ethyl acetate, 12ml isopropyl ethers
With the in the mixed solvent of 6ml water.At 25 DEG C, the suspension is beaten 5 hours.Afterwards, progressively should with 10 DEG C/h of speed
Suspension is cooled to -15 DEG C, and is kept for -15 DEG C stir 8 hours.Filtering, crystallization is washed with acetone, then is dried in vacuo 36 hours,
Obtain Farmorubine Hydrochloride crystallization.Yield 93%, purity 99.0%, the impurity without dimer or catabolite.
Embodiment 6
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 24ml ethyl acetate, 36 ml tetrahydrochysene furans
The in the mixed solvent muttered with 10ml water.At 30 DEG C, the suspension is beaten 4 hours.Afterwards, progressively with 10 DEG C/h of speed
The suspension is cooled to -10 DEG C, and is kept for -10 DEG C stir 12 hours.Filtering, crystallization is washed with acetone, then is dried in vacuo 24
Hour, obtain Farmorubine Hydrochloride crystallization.Yield 91%, purity 99.3%, the impurity without dimer or catabolite.
Embodiment 7
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 30ml Ethyl formates, 10ml methyl second
The in the mixed solvent of base ether and 2ml water.At 40 DEG C, the suspension is beaten 0.4 hour.Afterwards, progressively with 20 DEG C/h of speed
The suspension is cooled to -20 DEG C by rate, and is kept for -20 DEG C stir 2 hours.Filtering, crystallization is washed with acetone, then convection oven is dry
Dry 10 hours, obtain Farmorubine Hydrochloride crystallization.Yield 91.4%, purity 99.4%, the impurity without dimer or catabolite.
Embodiment 8
Take 10.0 g Farmorubine Hydrochloride amorphous substances（Purity 92.0%）It is suspended in 20ml methyl acetates, 60ml methyl-props
The in the mixed solvent of base ether and 34ml water.At 40 DEG C, the suspension is beaten 2 hours.Afterwards, progressively with 20 DEG C/h of speed
The suspension is cooled to -20 DEG C by rate, and is kept for -20 DEG C stir 12 hours.Filtering, crystallization is washed with acetone, then convection oven
Dry 10 hours, obtain Farmorubine Hydrochloride crystallization.Yield 91.8%, purity 99.4% is miscellaneous without dimer or catabolite
Matter.
Embodiment 9
C3 ~ C5 esters are propyl formates.
C3~C6 ethers are methyl isopropyl ethers.
Other steps are same as Example 1.
Embodiment 10
C3 ~ C5 esters are methyl propionates.
C3~C6 ethers are ether.
Other steps are same as Example 1.
Embodiment 11
C3 ~ C5 esters are isopropyl formates.
C3~C6 ethers are methyl tertiary butyl ether(MTBE)s.
Other steps are same as Example 1.
Embodiment 12
C3 ~ C5 esters are isopropyl acid methyl esters.
C3~C6 ethers are 1,4- dioxane.
Other steps are same as Example 1.
Embodiment 12
C3 ~ C5 esters are isopropyl acetates.
C3~C6 ethers are propyl ether.
Other steps are same as Example 1.
Embodiment 13
C3 ~ C5 esters are ethyl propionates.
Other steps are same as Example 1.
Embodiment 14
C3 ~ C5 esters are isopropyl acetoacetic esters.
Other steps are same as Example 1.
Claims (6)
1. a kind of preparation method of Farmorubine Hydrochloride crystallization, it is characterised in that：Comprise the following steps：
The mixed solvent of ester, ether and water is provided, the percent by volume of mixed solvent reclaimed water is 5% ~ 30%, the volume ratio of ester and ether is
3:1~1:3；
The ester is selected from C3 ~ C5 esters, and the ether is selected from C3~C6 ethers；
C3 ~ C5 esters are Ethyl formate, methyl acetate, ethyl acetate, propyl formate, methyl propionate, isopropyl formate, isopropyl
Sour methyl esters, propyl acetate, isopropyl acetate, ethyl propionate or isopropyl acetoacetic ester；
C3~C6 ethers are methyl ethyl ether, methyl-propyl ether, methyl isopropyl ether, ether, methyl tertiary butyl ether(MTBE), tetrahydrochysene furan
Mutter, 1,4- dioxane, propyl ether or isopropyl ether；
(b) by Farmorubine Hydrochloride amorphous substance is in the in the mixed solvent formation suspension of step (a) and is beaten；
The temperature of mashing is 20 DEG C ~ 40 DEG C, and after the completion of mashing, suspension is cooled into 0 DEG C ~ -20 DEG C；
(c) Farmorubine Hydrochloride crystallization is collected from the suspension.
2. the preparation method of Farmorubine Hydrochloride crystallization according to claim 1, it is characterised in that：Hydrochloric acid in step (b)
The mass volume ratio of Epi-ADM amorphous substance and mixed solvent is 1g:2mL~1g:15mL.
3. the preparation method of Farmorubine Hydrochloride crystallization according to claim 1, it is characterised in that：Step (b) mashing
Time is 2 ~ 6 hours.
4. the preparation method of Farmorubine Hydrochloride crystallization according to claim 1, it is characterised in that：Step (b) has been beaten
Cheng Hou, 0 DEG C ~ -20 DEG C are cooled to by suspension, and are kept stirring at such a temperature 8 ~ 15 hours.
5. the preparation method of Farmorubine Hydrochloride crystallization according to claim 1, it is characterised in that：The suspension it is cold
But speed is 10 DEG C/h ~ 20 DEG C/h.
6. the preparation method of Farmorubine Hydrochloride crystallization according to claim 1, it is characterised in that：In step (c), use
The crystallization separated out in suspension is separated and dried by the conventional method of this area.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510298163.7A CN104861014B (en) | 2015-06-03 | 2015-06-03 | A kind of preparation method of Farmorubine Hydrochloride crystallization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510298163.7A CN104861014B (en) | 2015-06-03 | 2015-06-03 | A kind of preparation method of Farmorubine Hydrochloride crystallization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104861014A CN104861014A (en) | 2015-08-26 |
| CN104861014B true CN104861014B (en) | 2017-09-29 |
Family
ID=53907241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510298163.7A Active CN104861014B (en) | 2015-06-03 | 2015-06-03 | A kind of preparation method of Farmorubine Hydrochloride crystallization |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104861014B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109384822B (en) * | 2017-08-11 | 2021-08-03 | 鲁南制药集团股份有限公司 | Epirubicin hydrochloride crystal form and preparation method thereof |
| CN109666050B (en) * | 2017-10-16 | 2023-09-12 | 鲁南制药集团股份有限公司 | Epirubicin hydrochloride crystal form III and preparation method thereof |
| CN109836466B (en) * | 2017-11-24 | 2024-01-19 | 鲁南制药集团股份有限公司 | Crystal form of epirubicin hydrochloride and preparation method thereof |
| CN109206309A (en) * | 2018-09-13 | 2019-01-15 | 山东省食品药品检验研究院 | A kind of isolation and purification method of doxorubicin hydrochloride impurity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1275953B1 (en) * | 1995-03-22 | 1997-10-24 | Sicor Spa | PROCEDURE FOR THE PREPARATION OF ANTIBIOTICS OF THE CLASS OF ANTHRACYCLINES |
| SI0848009T1 (en) * | 1996-12-16 | 2000-12-31 | Pharmachemie B.V. | A process for preparing epirubicin or acid addition salts thereof from daunorubicin |
| WO2005004805A2 (en) * | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| US7388083B2 (en) * | 2005-03-07 | 2008-06-17 | Solux Corporation | Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics |
| JP2008513519A (en) * | 2005-05-11 | 2008-05-01 | シコール インコーポレイティド | Stable lyophilized anthracycling lycoside |
| CN102120750B (en) * | 2011-01-30 | 2013-04-03 | 山东新时代药业有限公司 | Epirubicin hydrochloride purification method |
| DE102011103751A1 (en) * | 2011-05-31 | 2012-12-06 | Heraeus Precious Metals Gmbh & Co. Kg | Crystallization of epirubicin hydrochloride |
| EP2778171A1 (en) * | 2013-03-15 | 2014-09-17 | Synbias Pharma Ltd. | Crystalline monohydrate of epirubicin hydrochloride |
-
2015
- 2015-06-03 CN CN201510298163.7A patent/CN104861014B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104861014A (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI419651B (en) | Rebaudioside a composition and method for purifying rebaudioside a | |
| CN104861014B (en) | A kind of preparation method of Farmorubine Hydrochloride crystallization | |
| JP5149810B2 (en) | Method for producing amorphous, anhydrous crystalline or hydrated crystalline docetaxel | |
| CN105622535B (en) | A kind of preparation method of LCZ696 | |
| KR20010099806A (en) | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof | |
| EP3241837A1 (en) | Method for preparing sofosbuvir crystal form-6 | |
| CN105669679A (en) | Preparation method of PCI-32765 crystal form A | |
| JP2009542625A (en) | Improved production of high purity sucralose | |
| CN105693734B (en) | A kind of speciality ε-HNIW crystal and preparation method thereof | |
| CN106916142A (en) | A kind of method for preparing high-purity De Lasha stars | |
| CN109096129B (en) | Preparation method of L-carnitine tartrate | |
| CN107814802A (en) | A kind of new method for preparing citric acid tropsch imatinib medicinal crystal-form | |
| CN104193766A (en) | Method for preparing cefetamet acid | |
| WO2020015763A1 (en) | Calcium dibutyacyladenosine cyclophosphate salt crystal | |
| CN108558690B (en) | Crystal form of cycloserine esterified substance hydrochloride and preparation method thereof | |
| CN106279207A (en) | A kind of synthetic method of cefdinir | |
| WO2012010092A1 (en) | Preparation method and use of a crystal of a peptide substance | |
| CN105753732A (en) | Crystal form of AHU377 as well as preparation method and application thereof | |
| CN107827911B (en) | 7-phenylacetylaminocephalosporanic acid composite crystal and preparation method thereof | |
| CN109836466B (en) | Crystal form of epirubicin hydrochloride and preparation method thereof | |
| CN105669839A (en) | Hydrate of echinocandin B mother nucleus or salt thereof, preparation method and application thereof | |
| CN109384822B (en) | Epirubicin hydrochloride crystal form and preparation method thereof | |
| CN104610403B (en) | A kind of method of purification of super tylosin | |
| CN102219793B (en) | Method for purifying D (-)-sulbenicillin sodium | |
| JP2010229098A (en) | Method for producing type a crystal form of isoindoline derivative and type a crystal form of isoindoline derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20210707 Granted publication date: 20170929 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20240707 Granted publication date: 20170929 |
|
| PD01 | Discharge of preservation of patent |